Viktor Veniaminovich Tets
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jun 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Antiviral agent (US 10,299,480) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Method of producing a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid (US 10,584,095) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Agent against fungal infections (US 10,624,892) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,730,933 | Method for treating liver diseases of various origins In force · From the USPTO record | In force | From the USPTO record | |
| US 10,052,327 | Method for treating liver diseases of various origins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,277 | Fungicide In force · High confidence | In force | High confidence | |
| US 9,757,396 | Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,080,761 | Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,299,480 | Antiviral agent In force · From the USPTO record | In force | From the USPTO record | |
| US 10,253,037 | Drug with antiviral activity (variants) In force · From the USPTO record | In force | From the USPTO record | |
| US 10,624,892 | Agent against fungal infections In force · From the USPTO record | In force | From the USPTO record | |
| US 10,584,095 | Method of producing a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid In force · From the USPTO record | In force | From the USPTO record | |
| US 10,745,662 | Nutrient medium for cultivating bacteria In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.